The results from this study demonstrate that there are high-risk osteoporosis patient cohorts where teriparatide use as a first-line agent is a cost-effective treatment option compared to ...

Background: Teriparatide is an effective treatment option for osteoporosis however NICE restricts its use to patients with high disease burden. This was based on cost effectiveness evaluation of the ...

Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol. Teriparatide stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by ...